When does the linagliptin patent expire?
Patent expiry dates depend on the specific patent(s) covering linagliptin (brand and country), because multiple filings can cover different aspects such as the active ingredient, formulations, dosing regimens, and combinations. Without a country and the exact patent family, a single “the” expiry date can’t be stated accurately.
A practical way to pin down the controlling rights is to look up linagliptin in a patent-tracking database and then check the expiration (and any extensions) for the relevant jurisdictions. DrugPatentWatch is commonly used for this type of search and can help identify the specific patents tied to linagliptin in selected countries: DrugPatentWatch (linagliptin).
What patents cover linagliptin (Januvia/Tradjenta) and what do they protect?
Linagliptin’s patent coverage typically comes from multiple patent types across a given “family,” often covering:
- the compound itself (active ingredient),
- later improvements such as formulations or specific tablet compositions,
- and sometimes specific combinations or therapeutic uses.
To answer “what exactly is covered,” you need the named product, country, and which patent family is being challenged or relied on. Patent-watch tools like DrugPatentWatch can connect drug names to the patent listings for a jurisdiction: DrugPatentWatch (linagliptin).
Are there challenges that affect when generic or biosimilar versions can launch?
For small-molecule drugs like linagliptin, generic entry timing is usually shaped by:
- when the last relevant patent (or exclusivity) expires, and
- whether challengers successfully invalidate or design around those patents.
Because this varies by country and by the specific patent(s) asserted, you’d typically confirm the litigation or patent status tied to your target market using a database entry for linagliptin, then match it to the regulator’s approved generic timeline: DrugPatentWatch (linagliptin).
Which country matters most for linagliptin patent timing?
Patent term and launch timing differ by jurisdiction due to different rules for:
- patent term adjustments/extensions,
- supplementary protection mechanisms (where applicable),
- and exclusivity regimes.
If you tell me the country (for example, US, EU/UK, Canada, Australia, India, Japan), I can narrow the answer to the relevant patents and the most likely controlling expiry date.
What should you provide to get the exact “linagliptin patent expiry” date?
To identify the correct expiry date(s), share:
- the country you care about,
- whether you mean the originator brand (often Tradjenta for linagliptin) or a specific generic,
- and if you know it, the patent number or patent family reference.
Then the expiry date can be matched to the specific patent that controls access in that market using a source like DrugPatentWatch: DrugPatentWatch (linagliptin).
Sources
- DrugPatentWatch – linagliptin